Literature DB >> 17936740

Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.

Jason W Lane1, Nadja N Rehak, Glen L Hortin, Theoklis Zaoutis, Philip R Krause, Thomas J Walsh.   

Abstract

BACKGROUND: Acute increases in serum inorganic phosphorus (Pi) up to 4.75 mmol/l in the absence of hypocalcemia and tissue deposition of calcium phosphate were noted in 3 patients receiving liposomal amphotericin B (L-AMB). We investigated L-AMB as a possible cause of pseudohyperphosphatemia.
METHODS: Serum samples from the index patient were analyzed for Pi content by our laboratory's primary analyzer (Synchron LX20) and by an alternate analyzer (Vitros). Clear and lipemic serum pools, and normal saline, were spiked with L-AMB and analyzed by the LX20 Pi method. Ultrafiltration studies were performed on patient and spiked sera.
RESULTS: Increased Pi values were obtained only from the LX20 analyzer. There was a direct linear relationship between the concentration of L-AMB in the spiked samples and the LX20 Pi results, indicating a 0.9 mmol/l Pi increase for every 100 mg/l increase in L-AMB. Ultrafiltration normalized the Pi results.
CONCLUSION: Serum Pi results may be falsely increased in patients receiving L-AMB when measured by the LX20 analyzer. This novel cause of pseudohyperphosphatemia is due to interference of L-AMB with the method and is corrected by ultrafiltration of the specimen. Since the LX20 analyzer is widely used by the clinical laboratories clinicians and laboratory personnel should recognize this interference in order to avoid unnecessary diagnostic procedures and interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936740      PMCID: PMC2128727          DOI: 10.1016/j.cca.2007.08.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  22 in total

1.  Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B.

Authors:  D P Kontoyiannis; B S Andersson; R E Lewis; I I Raad
Journal:  Clin Infect Dis       Date:  2001-02-23       Impact factor: 9.079

2.  Pseudohyperphosphatemia associated with Waldenström's macroglobulinemia.

Authors:  M G Jamil; M M Abdel-Raheem; A Potti; R Levitt
Journal:  Am J Hematol       Date:  2000-12       Impact factor: 10.047

3.  Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation.

Authors:  Michelle A Barron; Margaret Lay; Nancy E Madinger
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 4.  The acidosis of exogenous phosphate intoxication.

Authors:  B Kirschbaum
Journal:  Arch Intern Med       Date:  1998-02-23

5.  Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient.

Authors:  J A Crompton; D Alexander; T Somerville; F S Shihab
Journal:  Transpl Infect Dis       Date:  2004-12       Impact factor: 2.228

6.  Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.

Authors:  T J Walsh; V Yeldandi; M McEvoy; C Gonzalez; S Chanock; A Freifeld; N I Seibel; P O Whitcomb; P Jarosinski; G Boswell; I Bekersky; A Alak; D Buell; J Barret; W Wilson
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

Review 8.  Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.

Authors:  R Nir-Paz; R Cohen; Y S Haviv
Journal:  Ren Fail       Date:  1999-09       Impact factor: 2.606

Review 9.  Magnesium and phosphorus.

Authors:  J R Weisinger; E Bellorín-Font
Journal:  Lancet       Date:  1998-08-01       Impact factor: 79.321

10.  Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.

Authors:  A C Leenders; S Daenen; R L Jansen; W C Hop; B Lowenberg; P W Wijermans; J Cornelissen; R Herbrecht; H van der Lelie; H C Hoogsteden; H A Verbrugh; S de Marie
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

View more
  5 in total

1.  Hyperphosphatemia in pediatric oncology patients receiving liposomal amphotericin B.

Authors:  Chad A Knoderer; Holly M Knoderer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 2.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

3.  Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.

Authors:  Nicole M Bohm; Katherine C Hoover; Amy E Wahlquist; Yusheng Zhu; Juan Carlos Q Velez
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Authors:  Andreas H Groll; Bart J A Rijnders; Thomas J Walsh; Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

5.  Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers.

Authors:  Monique Albersen; Arend Bökenkamp; Hans Schotman; Stephanie Smetsers
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.